Seres Therapeutics announces proposed public offering of common stock
Seres Therapeutics announced it is commencing an underwritten registered public offering of $60.0 million of shares of its common stock. Seres intends to grant underwriters a 30-day option to purchase up to an additional $9.0 million of shares of its common stock. June 12, 2019